**ASCO 2013**

(Case CCC Members **bold**)

**PRESENTATIONS**

**Anjali S. Advani, MD**  
Session Chair, *Education Session: Recent Breakthroughs in Acute Lymphoblastic Leukemia*  
Presenter, Optimal Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults  
Fri, May 31 3:00 PM - 4:15 PM; E354b

**Robert Dreicer, MD**  
Session Chair, *Clinical Problems in Oncology Session: Management of Challenging Genitourinary Tumors*  
Presenter, Adrenocortical Carcinoma: Systemic Therapies in the Adjuvant and Metastatic Setting  
Sat, Jun 1 8:00 AM - 9:15 AM; E451b

**Neal J. Meropol, MD**  
Session Chair, *Education Session: Raising the Bar: Setting Standards for Real Progress in Clinical Trials (eQ &A)*  
Presenter, Cost versus Value: Getting Our Money's Worth in Cancer Care  
Sat, Jun 1 8:00 AM - 9:15 AM; S100bc

**Lyndsay Harris, MD**  
Discussion Leader  
*Poster Discussion Session, Breast Cancer - HER2/ER*  
Sat, Jun 1 12:00 PM - 1:00 PM; E Hall D1

**Ronald M. Bukowski, MD**  
Session Chair, *Education Session: Renal Cell Carcinoma: New Insights for the Future*  
Presenter, New Targets and Strategies in Renal Cell Carcinoma: What Will the Future Hold?  
Sat, Jun 1 4:45 PM - 6:00 PM; E Arie Crown Theater
Mellar P. Davis, MD
Session Chair, Education Session: Supportive, Palliative, and End-of-Life Care: Similarities, Differences, and Integration
Presenter, Supportive Care
Sun, Jun 2 11:30 AM - 12:45 PM; E253

Nathan Pennell, MD
Discussion Leader, Molecular Testing in Lung Cancer: How Soon is Now?
Poster Discussion Session: Lung Cancer - Non-small Cell Metastatic
Sun, Jun 2 11:30 AM - 12:30 PM; E Hall D2

Afshin Dowlati, MD
Presenter, Appropriate Combination Strategies with Phosphatidylinositide 3-Kinases/Mammalian Target of Rapamycin Inhibitor Pathways
Education Session: Targeting the PI3K-Akt-mTOR Pathway: Success Stories, Resistance Mechanisms, Biomarkers, and Toxicities
Sun, Jun 2 4:45 PM - 6:00 PM; E354a

Mikkael Sekeres, MD
Presenter, Moving toward Better Outcomes in Myelodysplastic Syndromes
Educational Session: Diagnosis and Treatment of Myelodysplastic Syndromes/Myeloproliferative Neoplasms Overlap Syndromes
Sun, Jun 2 4:45 PM - 6:00 PM; E Arie Crown Theater

David J. Adelstein, MD
Presenter, Head and Neck Cancer
Highlights of the Day II Session Including Partners in Progress Award
Mon, Jun 3 8:00 AM - 9:30 AM; E Hall D1

Neal J. Meropol, MD
Presenter, Abstract 6500: Randomized trial of a web-based intervention to address barriers to clinical trials
Oral Abstract Session: Health Services Research
Mon, Jun 3 8:00 AM - 11:00 AM; S404

G. Thomas Budd, MD
Presenter, Abstract #CRA1008: S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer
Oral Abstract Session, Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Mon, Jun 3 9:45 AM - 12:45 PM; N Hall B1

Timothy D. Gilligan, MD, MSc
Discussion Leader: New Approaches to Advanced Gem Cell Cancers
Poster Discussion Session: Genitourinary (Nonprostate) Cancer
Tue, Jun 4 11:30 AM - 12:30 PM; E354a
PLENARY SESSION

1: RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)

Plenary Session: Central Nervous System Tumors
Sun, Jun 2 1:00 PM - 4:20 PM; N Hall B1
J Clin Oncol 31, 2013 (suppl; abstr 1)

Author(s): Mark R. Gilbert, James Dignam, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Kenneth D. Aldape, Howard Colman, Amab Chakravarti, Robert Jeraj, Terri S. Armstrong, Jeffrey Scott Wefel, Paul D. Brown, Kurt A. Jaekle, David Schiff, James Norman Atkins, David Brachman, Maria Werner-Wasik, Ritsuko Komaki, Erik P. Sulman, Minesh P. Mehta; University of Texas MD Anderson Cancer Center

Department of Neuro-Oncology, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Cleveland Clinic Foundation, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Arthur G. James Cancer Center, The Ohio State University, Columbus, OH; Department of Medical Physics, University of Wisconsin, Madison, WI; University of Texas Health Science Center School of Nursing, Houston, TX; Mayo Clinic, Jacksonville, FL; University of Virginia Medical Center, Charlottesville, VA; National Surgical Adjuvant Breast and Bowel Project and SCCC-CCOP, Goldboro, NC; Arizona Oncology Services Foundation, Phoenix, AZ; Thomas Jefferson University Hospital, Philadelphia, PA; University of Maryland, Baltimore, MD

CLINICAL SCIENCE SYMPOSIUM

LBA2010: Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM)

Clinical Science Symposium: Central Nervous System Tumor
Sun, Jun 2 8:00 AM - 9:30 AM; E253
J Clin Oncol 31, 2013 (suppl; abstr LBA2010)

Author(s): Erik P. Sulman, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Howard Colman, Robert B. Jenkins, Amab Chakravarti, Robert Jeraj, Paul D. Brown, Kurt A. Jaekle, David Schiff, James Dignam, James Norman Atkins, David Brachman, Maria Werner-Wasik, Ritsuko Komaki, Mark R. Gilbert, Minesh P. Mehta, Kenneth D. Aldape; The University of Texas MD Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Cleveland Clinic Foundation, Cleveland, OH; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Mayo Clinic, Rochester, MN; Arthur G. James Cancer Center, The Ohio State University, Columbus, OH; Department of Medical Physics, University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; University of Virginia Medical Center, Charlottesville, VA; National Surgical Adjuvant Breast and Bowel Project and
ORAL ABSTRACT SESSIONS

Sunday, June 2

500: Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Oral Abstract Session: Breast Cancer - HER2/ER
Sun, Jun 2 8:00 AM - 11:00 AM; N Hall B1
J Clin Oncol 31, 2013 (suppl; abstr 500)
Author(s): Lisa A. Carey, Donald A. Berry, David Ollila, Lyndsay Harris, Ian E. Krop, Douglas Weckstein, Norah Lynn Henry, Carey K. Anders, Constance Cirrincione, Eric P. Winer, Charles M. Perou, Clifford Hudis, Alliance; The University of North Carolina at Chapel Hill, Chapel Hill, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Case Western/Seidman Cancer Center, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; New Hampshire Oncology-Hematology, PA, Hooksett, NH; University of Michigan Medical Center, Ann Arbor, MI; The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Alliance Statistical Center, Duke University, Durham, NC; Memorial Sloan-Kettering Cancer Center, New York, NY

Monday, June 3

6500: Randomized trial of a web-based intervention to address barriers to clinical trials

Oral Abstract Session: Health Services Research
Mon, Jun 3 8:00 AM - 11:00 AM; S404
J Clin Oncol 31, 2013 (suppl; abstr 6500)
Author(s): Neal J. Meropol, Terrance Lynn Albrecht, Yu-Ning Wong, Al Bowen Benson, Joanne S. Buzaglo, Michael Collins, Jennifer Rachel Eads, Brian Egleston, Anne Lederman Flamm, Linda Fleisher, Michael S. Katz, Tyler G. Kinzy, Sharon Manne, Seunghee Margevicius, Dawn M. Miller, Suzanne M. Miller, David Poole, Nancy Roach, Eric A Ross, Mark D. Schluchter; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Kamanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Cancer Support Comunity, Research and Training Institute, Philadelphia, PA; Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH; International Myeloma Foundation, North Hollywood, CA; C3: Colorectal Cancer Coalition, Alexandria, VA
CRA1008: S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer
Oral Abstract Session: Breast Cancer – Triple Negative/Cytotoxics/Local Therapy
Mon, Jun 3 9:45 AM - 12:45 PM; N Hall B1
J Clin Oncol 31, 2013 (suppl; abstr CRA1008)
Author(s): G. Thomas Budd, William E. Barlow, Halle C. F. Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Jonathan K. Cho, Kristine Rinn, Kathy S. Albain, Helen K. Chew, Gary Von Burton, Timothy David Moore, Gordan Skalovic, Bradley Alexander McGregor, Lawrence E. Flaherty, Robert B. Livingston, Danika Lew, Julie Gralow, Gabriel N. Hortobagyi; Cleveland Clinic, Cleveland, OH; Cancer Research and Biostatistics, Seattle, WA; Mayo Clinic, Rochester, MN; Baystate Medical Center, Springfield, MA; Lombardi Comprehensive Cancer Center, Washington, DC; Allan Blair Cancer Center, Saskatoon, SK, Canada; Oncare Hawaii, Honolulu, HI; Swedish Cancer Institute, Seattle, WA; Loyola University Medical Center, Maywood, IL; University of California, Davis Cancer Center, Sacramento, CA; LSU Health Sciences Center, Shreveport, LA; Mid Ohio Oncology Hematology, Inc., Columbus, OH; Sparrow Regional Cancer Center, Lansing, MI; Willford Hall Medical Center, Lackland, TX; Wayne State University School of Medicine, Detroit, MI; Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX

3007: Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival
Oral Abstract Session: Developmental Therapeutics - Immunotherapy
Mon, Jun 3 3:00 PM - 6:00 PM; S406
J Clin Oncol 31, 2013 (suppl; abstr 3007)
Author(s): Gabriela R. Rossi, Jeffrey M Hardacre, Mary Frances Mulcahy, Mark S. Talamonti, Jennifer Carrie Obel, Caio Max S. Rocha Lima, Howard Safran, Heinz-Josef Lenz, E. Gabriela Chiorean, Nicholas N. Vahanian, Charles J. Link, NLG0205; NewLink Genetics, Ames, IA; University Hospitals Case Medical Center, Cleveland, OH; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Kellogg Cancer Center NorthShore University Health System, Evanston, IL; NorthShore University Health System, Evanston, IL; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Brown University Oncology Research Group, Providence, RI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Tuesday, June 4

7008: Impact of allogeneic hematopoietic stem cell transplant (H SCT) on patients harboring the spliceosome mutation SRSF2
Oral Abstract Session: Leukemia, Myelodysplasia, and Transplantation
Tue, Jun 4 8:00 AM - 11:00 AM; E354b
J Clin Oncol 31, 2013 (suppl; abstr 7008)
Author(s): Betty Ky Hamilton, Ali Tabarroki, Paul Elson, Edy Hasrouni, Valeria Visconte, Shawnda Tench, Matt E. Kalaycio, Mikkael A. Sekeres, Ronald M. Sobecks, Hien Kim
**Saturday, June 1**

**514: Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer**

Poster Discussion Session (Display): Breast Cancer - HER2/ER  
Sat, Jun 1 8:00 AM - 12:00 PM; E450b  
Poster Discussion Session (Discussion): Breast Cancer - HER2/ER  
Sat, Jun 1 12:00 PM - 1:00 PM; E Hall D1  
J Clin Oncol 31, 2013 (suppl; abstr 514)  
Author(s): Aki Morikawa, **David M. Peereboom**, Quentin R Smith, Helen Thorsheim, Paul R Lockman, Ahkeem James Simmons, **Robert J. Weil**, Viviane Tabar, Patricia Schriver Steeg, Andrew David Seidman; Memorial Sloan-Kettering Cancer Center, New York, NY; Cleveland Clinic, Cleveland, OH; Texas Tech University Health Sciences Center, Amarillo, TX; Texas Tech University Health Science Center, Amarillo, TX; Women’s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, MD

**5023: Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-3501 trial**

Poster Discussion Session (Display): Genitourinary (Prostate) Cancer  
Sat, Jun 1 8:00 AM - 12:00 PM; E450a  
Poster Discussion Session (Discussion): Genitourinary (Prostate) Cancer  
Sat, Jun 1 12:00 PM - 1:00 PM; E Arie Crown Theater  
J Clin Oncol 31, 2013 (suppl; abstr 5023)  
Author(s): Michael Thomas Schweizer, Peng Huang, Cora N. Stemberg, Ronald De Wit, Evelyne Brana Ecstein-Frasise, **Michael W. Kattan**, Adam S Kibel, Mario A. Eisenberger; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Medical Oncology, San Camillo and
Forlanini Hospitals, Rome, Italy; Erasmus MC, Rotterdam, Netherlands; Sanofi, Vitry-sur-Seine, France; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH; Brigham and Women's Hospital/Harvard University, Boston, MA

**5029: Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome**

Poster Discussion Session (Display): Genitourinary (Prostate) Cancer
Sat, Jun 1 8:00 AM - 12:00 PM; E450a

Poster Discussion Session (Discussion): Genitourinary (Prostate) Cancer
Sat, Jun 1 12:00 PM - 1:00 PM; E Arie Crown Theater

J Clin Oncol 31, 2013 (suppl; abstr 5029)

Author(s): Eric A. Klein, Sara Moscovita Falzarano, Nan Zhang, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Diana B. Cherbaavaz, Robert J. Pelham, Carl Millward, Mark Lee, Cristina Magi-Galluzzi; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Genomic Health, Inc., Redwood City, CA

**7010: Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML)**

Poster Discussion Session (Display): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 8:00 AM - 12:00 PM; S405

Poster Discussion Session (Discussion): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 12:00 PM - 1:00 PM; S406

J Clin Oncol 31, 2013 (suppl; abstr 7010)

Author(s): Antonio Martin Jimenez, Marcos De Lima, Uday R. Popat, Gautam Borthakur, Lynne Abruzzo, Borje Andersson, Guillermo Garcia-Manero, Elias Jabbour, Julienne Chen, Qaiser Bashir, Stefan O. Ciurea, Partow Kebriaei, Sairah Ahmed, Issa F. Khouri, Piyanuch Kongtim, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin, Betul Oran; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

**7011: Allogeneic transplantation for myelofibrosis: Benefit of dose intensity**

Poster Discussion Session (Display): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 8:00 AM - 12:00 PM; S405

Poster Discussion Session (Discussion): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 12:00 PM - 1:00 PM; S406

J Clin Oncol 31, 2013 (suppl; abstr 7011)

Author(s): Uday R. Popat, Roland Bassett, Julienne Chen, Amin Majid Alousi, Paolo Andelini, Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Partow Kebriaei, Issa F. Khouri, Sergej Konoplev, Marcos De Lima, Yago Nieto, Betul Oran, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Srdan Verstovsek, Borje Andersson, Richard E. Champlin; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Biostatistics, The
University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematopathology Adm, The University of Texas MD Anderson Cancer Center, Houston, TX; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

7028: SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)
Poster Discussion Session (Display): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 8:00 AM - 12:00 PM; S405
Poster Discussion Session (Discussion): Leukemia, Myelodysplasia, and Transplantation
Sat, Jun 1 12:00 PM - 1:00 PM; S406
J Clin Oncol 31, 2013 (suppl; abstr 7028)
Author(s): Anjali S. Advani, Shannon McDonough, Edward Copelan, Cheryl L. Willman, Deborah A. Mulford, Alan F. List, Mikkael A. Sekeres, Megan Othus, Harry P. Erba, Frederick R. Appelbaum; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; SWOG Statistical Center, Seattle, WA; Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC; University of New Mexico Cancer Center, Albuquerque, NM; University of Rochester Medical Center, Rochester, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Alabama at Birmingham, Birmingham, AL; Fred Hutchinson Cancer Research Center, Seattle, WA

10526: Using pegylated arginine deiminase (ADI-PEG20) for the treatment of sarcomas that lack argininosuccinate synthetase 1 expression
Poster Discussion Session (Display): Sarcoma
Sat, Jun 1 8:00 AM - 12:00 PM; S102
Poster Discussion Session (Discussion): Sarcoma
Sat, Jun 1 12:00 PM - 1:00 PM; S100a
J Clin Oncol 31, 2013 (suppl; abstr 10526)
Author(s): Brian Andrew Van Tine, Gregory R Bean, Phillip Boone, Munir Tanas, Matthew B Schulze, David Y Chen, John S. Bomalaski, Brian Rubin; Washington University in St. Louis, St. Louis, MO; Cleveland Clinic Foundation, Cleveland, OH; Polaris Pharmaceuticals, San Diego, CA; Cleveland Clinic, Cleveland, OH

3014: Immune gene expression in primary melanomas to predict lower risk of recurrence and death
Poster Discussion Session (Display): Developmental Therapeutics - Immunotherapy
Sat, Jun 1 1:15 PM - 5:15 PM; S405
Poster Discussion Session (Discussion): Developmental Therapeutics - Immunotherapy
Sat, Jun 1 4:45 PM - 5:45 PM; S406
J Clin Oncol 31, 2013 (suppl; abstr 3014)
Author(s): Shanthi Sivendran, Rui R. Chang, Sara Harcharik, Lawrence Hall, Sebastian Bernardo, Marina Moskalenko, Robert Phelps, Meera Svendran, Ariella Cohain, Analisa Difeo, Michael Parides, Mark Lebwohl, Philip Friedlander, Jacques Banchereau, Nina Bhardwaj, William K. Oh, Steven J. Burakoff, Karolina Palucka, Miriam Merad, Yvonne M. Sænger; Hematology/Oncology Medical Specialists, Lancaster General Health, Lancaster, PA; Mount Sinai School of Medicine, New York, NY; Department of Dermatology, Geisinger Health Systems, Danville, PA; Case Comprehensive Cancer
Center, Case Western Reserve University, Cleveland, OH; Icahn School of Medicine, Mount Sinai Medical Center, New York, NY; Baylor Institute for Immunology Research, Dallas, TX; New York University, New York, NY; Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; The Tisch Cancer Institute, New York, NY

6035: A phase III randomized trial of two cisplatin-based concurrent chemoradiation (CCRT) regimens for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
Poster Discussion Session (Display): Head and Neck Cancer
Sat, Jun 1 1:15 PM - 5:15 PM; E450a
Poster Discussion Session (Discussion): Head and Neck Cancer
Sat, Jun 1 4:45 PM - 5:45 PM; E354a
J Clin Oncol 31, 2013 (suppl; abstr 6035)
Author(s): Cristina P. Rodríguez, David J. Adelstein, Lisa A. Rybicki, Panayiotis Savvides, Jerrold P. Saxton, Shilomo A. Koyfman, John Greskovich, Min Yao, Joseph Scharpf, Pierre Lavertu, Benjamin J. Wood, Brian Burkey, Robert Lorenz, Rod Rezaee, Chad Zender, Denise I. Ives; Oregon Health & Science University, Portland, OR; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; Cleveland Clinic, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

9517: The role of age on dose-limiting toxicities (DLTs) in phase I dose-escalation trials
Poster Discussion Session (Display): Patient and Survivor Care
Sat, Jun 1 1:15 PM - 5:15 PM; S102
Poster Discussion Session (Discussion): Patient and Survivor Care
Sat, Jun 1 4:45 PM - 5:45 PM; S100a
J Clin Oncol 31, 2013 (suppl; abstr 9517)
Author(s): Anita Schwandt, Pamela J. Harris, Sally Hunsberger, Amélie Deleporte, Gary L. Smith, Diana Vulih, Barry Douglas Anderson, S. Percy Ivy; Case Western Reserve University School of Medicine, Cleveland, OH; National Cancer Institute, Bethesda, MD; Institut Jules Bordet, Brussels, Belgium; Cancer Therapeutics Evaluation Program, National Cancer Institute, Bethesda, MD; Theradex Systems, Inc., Princeton, NJ; Theradex, Princeton, NJ; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Sunday, June 2

1508: Time-related changes in yield and harms of screening breast MRI
Poster Discussion Session (Display): Cancer Prevention/Epidemiology: Epidemiology
Sun, Jun 2 8:00 AM - 12:00 PM; S102
Poster Discussion Session (Discussion): Cancer Prevention/Epidemiology: Epidemiology
Sun, Jun 2 11:30 AM - 12:30 PM; S100a
J Clin Oncol 31, 2013 (suppl; abstr 1508)
Author(s): **Holly Jane Pederson**, Colin O'Rourke, Lauren D Bolden, Sobia Khan, Manisha Yadav, Joanne Lyons, Laura Shepardsdon, Alice Rim, Joseph P. Crowe, Stephen R. Grobmyer; Cleveland Clinic, Cleveland, OH; Howard University, Washington, DC; Baylor College of Medicine, Houston, TX

**1527: Second malignant neoplasms (SMN) in Cowden syndrome patients with underlying germline PTEN mutations**

Poster Discussion Session (Display): Cancer Prevention/Epidemiology  
Sun, Jun 2 8:00 AM - 12:00 PM; S102  
Poster Discussion Session (Discussion): Cancer Prevention/Epidemiology  
Sun, Jun 2 11:30 AM - 12:30 PM; S100a  
J Clin Oncol 31, 2013 (suppl; abstr 1527)

Author(s): Joanne YY Ngeow, Jessica Mester, Haider Mahdi, Lamis Yehia, **Jill Bamholtz-Sloan, Charis Eng**; Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH

**5530: Locally advanced adenocarcinoma and adenosquamous carcinoma of the cervix compared to squamous cell carcinoma of the cervix in Gynecologic Oncology Group trials of chemoradiation**

Poster Discussion Session (Display): Gynecologic Cancer  
Sun, Jun 2 8:00 AM - 12:00 PM; E450a  
Poster Discussion Session (Discussion): Gynecologic Cancer  
Sun, Jun 2 11:30 AM - 12:30 PM; E354b  
J Clin Oncol 31, 2013 (suppl; abstr 5530)

Author(s): **Peter Graham Rose**, James Java, Charles W. Whitney, Henry Keys, Rachael Lanciano, Gillian Thomas; Cleveland Clinic Foundation, Cleveland, OH; Gynecologic Oncology Group, Buffalo, NY; Christiana Gynecologic Oncology, Newark, DE; AO Fox Hospital, Voorheesville, NY; Delaware County Memorial Hospital, Drexal Hill, PA; Sunnybrook Health Sciences Centre, Toronto, ON, Canada

**6525: Black-white disparity in physical performance among older women with breast cancer: The role of physical activity and inflammation**

Poster Discussion Session (Display): Health Services Research  
Sun, Jun 2 8:00 AM - 12:00 PM; S405  
Poster Discussion Session (Discussion): Health Services Research  
Sun, Jun 2 11:30 AM - 12:30 PM; S406  
J Clin Oncol 31, 2013 (suppl; abstr 6525)

Author(s): **Cynthia Owusu, Mark D. Schluchter, Siran M. Koroukian**, Kathryn Schmitz, **Nathan A. Berger**; Case Western Reserve University, Cleveland, OH; University of Pennsylvania, Philadelphia, PA

**Monday, June 3**

**2033: Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results**
Tuesday, June 4

4515: A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC)
Poster Discussion Session (Display): Genitourinary (Nonprostate) Cancer
Tue, Jun 4 8:00 AM - 12:00 PM; E450b
Poster Discussion Session (Discussion): Genitourinary (Nonprostate) Cancer
Tue, Jun 4 11:30 AM - 12:30 PM; E354a
J Clin Oncol 31, 2013 (suppl; abstr 4515)
Author(s): Brian I. Rini, Laura S. Wood, Paul Elson, Hui Zhu, Namita Chittoria, Kriti Mittal, Robert Dreicer, Timothy D. Gilligan, Shetal N. Shah, Jorge A. Garcia; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Imaging Institute, Cleveland Clinic Foundation, Cleveland, OH

4520: Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)
Poster Discussion Session (Display): Genitourinary (Nonprostate) Cancer
Tue, Jun 4 8:00 AM - 12:00 PM; E450b
Poster Discussion Session (Discussion): Genitourinary (Nonprostate) Cancer
Tue, Jun 4 11:30 AM - 12:30 PM; E354a
J Clin Oncol 31, 2013 (suppl; abstr 4520)
Author(s): Andrew B. Nixon, Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, Herbert Hurwitz, Eric Jay Small, Brian I. Rini, Phillip G. Febbo, Daniel J. George, for the Alliance for Clinical Trials in Oncology; Duke University Medical Center, Durham, NC; Department of Biostatistics and Bioinformatics, Duke University and Alliance Statistical and Data Center, Durham, NC; St Luke's-Roosevelt Hospital Center, Continuum Cancer Centers of New York, New York, NY; Forsyth Regional Cancer Center, Winston-Salem, NC; University of California, San Francisco, San Francisco, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Saturday, June 1

2044: Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma
General Poster Session: Central Nervous System Tumors
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 2044)
Author(s): Jaishri O'Neill Blakeley, Joy D. Fisher, Frank S. Lieberman, Janine Lupo, Louis B. Nabors, Jason Crane, Patrick Y. Wen, Andre Cote, David M. Peereboom, Qiuting Wen, Timothy Francis Cloughesy, H. Ian Robins, Serena Desideri, Stuart A. Grossman, Xiaobu Ye, Sarah Nelson, The Adult Brain Tumor Consortium; The Johns Hopkins University, School of Medicine, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of California, San Francisco, San Francisco, CA; University of Alabama at Birmingham, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Cleveland Clinic, Cleveland, OH; David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; University of Wisconsin Hospitals and Clinics, Madison, WI

2065: Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data
General Poster Session: Central Nervous System Tumors
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 2065)
Author(s): Lawrence Kleinberg, Jeffrey G. Supko, Tom Mikkelsen, Jaishri O'Neill Blakeley, Glen Stevens, Xiaobu Ye, Serena Desideri, Samuel Ryu, Bhardwaj Desai, Vincent L. Giranda, Stuart A. Grossman; The Johns Hopkins University, Baltimore, MD; Massachusetts General Hospital, Boston, MA; Henry Ford Health System, Detroit, MI; The Johns Hopkins University, School of Medicine, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Henry Ford Hospital, Detroit, MI; Abbott Laboratories, Abbott Park, IL

2070: A validation study of graded prognostic assessment index for lung cancer patients with brain metastases
General Poster Session: Central Nervous System Tumors
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 2070)
Author(s): Lingling Du, Vyshak Alva Venur, Saurabhb Dahiya, Rohan Garje, Kwabena Osei-Boateng, Paul Elson, John H. Suh, Samuel T. Chao, Manmeet Singh Ahluwalia;
2096: Graded prognostic assessment index for breast cancer patients with brain metastases (BCBM)

General Poster Session: Central Nervous System Tumors
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 2096)
Author(s): Vyshak Alva Venur, Saurabh Dahiya, Lingling Du, Rohan Garje, Kwabena Osei-Boateng, Paul Elson, John H. Suh, Samuel T. Chao, Manmeet Singh Ahluwalia; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic/Fairview, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation-Department of Translational Hematology and Oncology Research, Cleveland, OH

6045: A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)

General Poster Session: Head and Neck Cancer
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 6045)
Author(s): Priscila Hermont Goncalves, Shivaani Kummar, Lillian L. Siu, Aaron Richard Hansen, Panayiotis Savvides, Ammar Sukari, Joseph Chao, Lance K. Heilbrun, Mary Jo Pilat, Daryn W. Smith, Lindsay Casetta, Scott Anthony Boemer, Patricia LoRusso; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, MD; Princess Margaret Cancer Center, Toronto, ON, Canada; Princess Margaret Cancer Center, University Health Network, Division of Medical Oncology & Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; City of Hope Cancer Center/Beckman Research Institute, Duarte, CA

6061: Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer: A retrospective analysis

General Poster Session: Head and Neck Cancer
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 6061)
Author(s): Tobenna Igewonu Nwizu, Lisa A. Rybicki, Deborah Chute, Cristina P. Rodriguez, Shlomo A. Koyfman, John Greskovich, Jerrold P. Saxton, Joseph Scharpf, Robert Lorenz, Brian Burkey, Benjamin J. Wood, Mumtaz Khan, Samer Al-khudari, Aaron P. Hoschar, Denise I. Ives, Joanna Bodmann, David J. Adelstein; Cleveland Clinic Foundation, Cleveland, OH; Oregon Health & Science University, Portland, OR; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
8044: Serum and tumor biomarkers to predict outcome in the eLung trial, a multicenter, randomized phase IIb study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC)
General Poster Session: Lung Cancer - Non-small Cell Metastatic
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 8044)
Author(s): Paul J. E. Miller, Mark S. Walker, Kurt W. Tauer, James Atkins, Kulumani M Svarajan, Vipul M. Patel, Bruno R. Bastos, Krista Meyer, Joanna Roder, Lisa Uyeda, Suzanne Salazar, Corey J. Langer, Mark A. Socinski, David R. Spigel, Lee Steven Schwartzberg; ACORN Research, Memphis, TN; The West Clinic, Memphis, TN; Southeastern Medical Oncology Center, Goldsboro, NC; Joliet Oncology and Hematology Associates, Joliet, IL; Gaston Hematology and Oncology, Gastonia, NC; Cleveland Clinic Florida, Weston, FL; Biodesix Inc., Boulder, CO; Biodesix Inc., Broomfield, CO; Clarient, Inc., Aliso Viejo, CA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA; Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; ACORN Research and The West Clinic, Memphis, TN

8113: Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC)
General Poster Session: Lung Cancer - Non-small Cell Metastatic
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 8113)
Author(s): Hui Zhu, Andria Valeria Arrossi, Paul Elson, Carol Farver, Raymond R. Tubbs, Sudish C. Murthy, David P. Mason, Peter J. Mazzone, Nathan A. Pennell; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Respiratory Institute, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

8114: Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses
General Poster Session: Lung Cancer - Non-small Cell Metastatic
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 8114)
Author(s): Balazs Halmos, Nathan A. Pennell, Gregory Alan Otterson, Shirish M. Gadgeel, Tarek Mekhall, Michael Robert Snell, J. Phillip Kuebler, Pingfu Fu, Neelesh Sharma, Afshin Dowlati; New York-Presbyterian Hospital, Columbia University, New York, NY; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Florida Hospital Cancer Institute, Orlando, FL; MetroHealth Medical Center, Cleveland, OH; Columbia Oncology Associates, Columbus, OH; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland,
OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

9086: Graded prognostic assessment index for melanoma with brain metastases (MBM)
General Poster Session: Melanoma/Skin Cancers
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 9086)
Author(s): Kwabena Osei-Boateng, Vyshak Alva Venur, Saurabh Dahiya, Lingling Du, Rohan Garje, Paul Elson, Samuel T. Chao, Manmeet Singh Ahluwalia; Cleveland Clinic Foundation, Cleveland, OH; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland Clinic, OH; Cleveland Clinic/Fairview, Cleveland, OH; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH

TPS2104: Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas
General Poster Session: Central Nervous System Tumors
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr TPS2104)
Author(s): Andrew David Norden, David Schiff, Manmeet Singh Ahluwalia, Glenn Jay Lesser, Lakshmi Nayak, Eudocia Quant Lee, Alona Muzikansky, Jorg Dietrich, Katrina H. Smith, Sarah C. Gaffey, Christine Sceppa McCluskey, Keith L. Ligon, David A. Reardon, Patrick Y. Wen; Dana-Farber Cancer Institute, Boston, MA; University of Virginia Medical Center, Charlottesville, VA; Cleveland Clinic, Cleveland, OH; Wake Forest University, School of Medicine, Winston-Salem, NC; Massachusetts General Hospital Cancer Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute/Brigham and Women's Hospital/ Boston Children's Hospital, Boston, MA

TPS9103: CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM)
General Poster Session: Melanoma/Skin Cancers
Sat, Jun 1 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr TPS9103)
Author(s): F. Stephen Hodi, Asim Amin, Yvonne M. Saenger, Gregory K. Pennock, Troy H. Guthrie, April K. Salama, Lawrence E. Flaherty, Henry B. Koon, David H. Lawson, Montaser F. Shaheen, Agnes Balogh, Cyril Konto, Steven O'Day; Dana-Farber Cancer Institute, Boston, MA; Levine Cancer Institute, Charlotte, NC; Mount Sinai School of Medicine, New York, NY; M. D. Anderson Cancer Center, Orlando, Orlando, FL; Baptist Cancer Institute, Jacksonville, FL; Duke Cancer Institute, Durham, NC; Wayne State University School of Medicine, Detroit, MI; University Hospitals of Cleveland, Cleveland, OH; Emory University School of Medicine, Atlanta, GA; University of New Mexico Cancer Center, Albuquerque, NM; Bristol-Myers Squibb, Braine-l’Alleud, Belgium; Bristol-Myers Squibb, Wallingford, CT; The Beverly Hills Cancer Center, Beverly Hills, CA

619: Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study
General Poster Session: Breast Cancer - HER2/ER
1038: A retrospective comparison of the characteristics and recurrence outcome of triple-negative and triple-positive breast cancer
General Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Sat, Jun 1 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 1038)
Author(s): Jaskirat Singh Randhawa, Vyshak Alva Venur, Hameem Kawsar, Timothy Peter Spiro, Abdo S. Haddad, Rajesh Kumar Bagai, Hamed Daw; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Cancer Center, Cleveland, OH; Cleveland Clinic Cancer Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH

1046: TGFb signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC)
General Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Sat, Jun 1 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 1046)
Author(s): Nicole Williams, Vinay Varadan, Aditi Vadodkar, Kristy Miskimen, Hannah L. Gilmore, Nicholas Beckloff, Simone Edelheit, Dhiya Prabhakar, Angel Janeski, Nila Banerjee, Sitharthan Kamalakaran, Maysa M. Abu-Khalaf, William M. Sikov, Nevenka Dimitrova, Lyndsay Harris; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Philips Research North America, Briarcliff Manor, NY; University Hospital/Case Western Reserve University, Cleveland, OH; Case Western Reserve, Cleveland, OH; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI; Case Western/Seidman Cancer Center, Cleveland, OH

1069: Insurance status as a strong predictor of outcome in triple-negative breast cancer (TNBC): A multi-institutional retrospective study
General Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Sat, Jun 1 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 1069)
Author(s): Tithi Biswas, Shreya Prasad, Timothy Zagar, Jimmy Efird, Sarah E. James, Paul R. Walker, Rachel Elizabeth Raab, Lisa A. Carey, Lawrence B. Marks; Radiation Oncology, University Hospitals Case Medical Center, Case Western University, Cleveland, OH; University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Radiation Oncology - University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Public Health, East Carolina University at Brody School of Medicine, Greenville, NC; Brody School of Medicine at East Carolina University, Greenville, NC; Leo Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC; The University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC

Sunday, June 2

4087: A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, surgery and post-operative concurrent cisplatin and fluorouracil chemoradiotherapy (CRT) in patients (pts) with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GE)
General Poster Session: Gastrointestinal (Noncolorectal) Cancer
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 4087)
Author(s): Michael J. McNamara, Thomas W. Rice, Lisa A. Rybicki, Cristina P. Rodriguez, Gregory M. M. Videtic, Jerrold P. Saxton, Kevin L. Stephans, John Greskovich, Davendra Sohal, David P. Mason, Sudish C. Murthy, Denise I. Ives, Joanna Bodmann, David J. Adelstein; Cleveland Clinic Foundation, Cleveland, OH; Oregon Health & Science University, Portland, OR; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

7036: Cutaneous complications in hematopoietic cell transplant recipients: Impact of biopsy on patient management
General Poster Session: Leukemia, Myelodysplasia, and Transplantation
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 7036)
Author(s): Oana Valeria Paun, Tycel Jovelle Phillips, Ping Fu, Robert Novoa, Kord Honda, Kurt Quoc Lu, Hillard M. Lazarus; Case Western Reserve University, Cleveland, OH; University of Michigan, Ann Arbor, MI; Case Comprehensive Cancer Center, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; University Hospitals, Cleveland, OH

7054^: Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd
General Poster Session: Leukemia, Myelodysplasia, and Transplantation
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 7054^)
Author(s): Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, Surapol Issaragrisil, Anna G. Turkina, Juan Luis Steegmann, Jose L. Lopez, Chiaki Nakaseko, Matt E. Kalaycio, Francoise Huguet, Charisse N. Kemp, Xiaolin Fan, Hans D. Menssen, Hagop M. Kantarjian, Andreas Hochhaus; University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy; Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia; The University of Chicago, Chicago, IL; Mahidol University, Siriraj Hospital, Bangkok, Thailand; Hematology Research Center, Moscow, Russia; Hospital Universitario de la Princesa, Madrid, Spain; Banco Municipal de Sangre, Dpt. Clinicas Hematologicas, Esq. Pirineos, Caracas, DC, Venezuela; Chiba University Hospital, Department of Hematology, Chiba, Japan; Cleveland Clinic, Cleveland, OH; Hospital de Purpan, Toulouse, France; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; The University of Texas MD Anderson Cancer Center, Houston, TX; Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany

7058: Phase I study of midostaurin and azacitidine in relapsed and elderly AML
General Poster Session: Leukemia, Myelodysplasia, and Transplantation
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 7058)
Author(s): Brenda W. Cooper, Tamila L. Kindwall-Keller, Hillard M. Lazarus, Mehdi Hamadani, William W. Tse, Soumit K. Basu, Michael Craig; University Hospital of Cleveland, Case Medical Center, Cleveland, OH; University of Virginia, Charlottesville, VA; University Hospitals Case Medical Center, Cleveland, OH; Osborn Hematopoietic Malignancy and Transplant Program, West Virginia University, Morgantown, WV; Osborn Hematopoietic Malignancy and Transplant Program, West Virginia University, Morgantown, WV

7126: Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza)
General Poster Session: Leukemia, Myelodysplasia, and Transplantation
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 7126)
Author(s): Amer Zeidan, Zhuoxin Sun, Thomas Prebet, Peter Greenberg, Mark Juckett, Mitchell Reed Smith, Elisabeth Paietta, Janice Lynn Gabrilove, Harry P. Erba, Steven Gore, Martin S. Tallman, on behalf of the Eastern Cooperative Oncology Group; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; France and Aix-Marseille University, Marseille, France; Stanford University, Stanford, CA; University of Wisconsin, Madison, WI; Cleveland Clinic, Cleveland, OH; Montefiore Medical Center - North Division, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan-Kettering Cancer Center, New York, NY

8585*: MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI)
General Poster Session: Lymphoma and Plasma Cell Disorders
Sun, Jun 2 8:00 AM - 11:45 AM; S Hall A2
Monday, June 3

2587: Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer

General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2

4565: Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium

General Poster Session: Genitourinary (Nonprostate) Cancer
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2
4578: Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy

General Poster Session: Genitourinary (Nonprostate) Cancer
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 4578)

Author(s): Nils Kroeger, Jae-Lyun Lee, Georg A. Bjamason, Jennifer J. Knox, Mary J. MacKenzie, Ulka N. Vaishamayan, Lori Wood, Sandy Srinivas, Sun Young Rha, Sumanta Kumar Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Min-Han Tan, Aristotelis Bamias, Christian K. Kollmannsberger, Scott A. North, Brian I. Rini, Toni K. Choueiri, Daniel Yick Chin Heng; Tom Baker Cancer Centre, Calgary, AB, Canada; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Center, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada; Kamanos Cancer Institute, Wayne State University, Detroit, MI; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Stanford Medical Center, Stanford, CA; Yonsei Cancer Center/Yonsei University College of Medicine, Seoul, South Korea; City of Hope Comprehensive Cancer Center, Duarte, CA; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; National Cancer Centre Singapore, Singapore, Singapore; Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece; BC Cancer Agency, Vancouver, BC, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA

4586: First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)

General Poster Session: Genitourinary (Nonprostate) Cancer
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 4586)

Author(s): Daniel Yick Chin Heng, Brian I. Rini, Jae-Lyun Lee, Nils Kroeger, Sandy Srinivas, Lauren Christine Harshman, Jennifer J. Knox, Georg A. Bjamason, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Neeraj Agarwal, Sumanta Kumar Pal, Min-Han Tan, Sun Young Rha, Takeshi Yuasa, Frede Donskov, Aristotelis Bamias, Scott A. North, Toni K. Choueiri; Tom Baker Cancer Centre, Calgary, AB, Canada; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Stanford Medical Center, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Princess Margaret Cancer Center, Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Kamanos Cancer Institute, Wayne State University, Detroit, MI; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; City of Hope, Duarte, CA; Institute of Bioengineering and Nanotechnology, Singapore, Singapore; Yonsei Cancer Center/Yonsei University
College of Medicine, Seoul, South Korea; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Alexandra Peripheral General Hospital, Athens, Greece; Cross Cancer Institute, Edmonton, AB, Canada

**TPS4590: ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma**

General Poster Session: Genitourinary (Nonprostate) Cancer  
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2  
J Clin Oncol 31, 2013 (suppl; abstr TPS4590)

Author(s): Andrew J. Armstrong, Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R Jones, Ulka N. Vaishampayan, Jorge A. Garcia, Robert E. Hawkins, Christian K. Kollmannsberger, Christine Lusk, Samuel Broderick, Daniel J. George; Duke Cancer Institute, Durham, NC; Duke University Medical Center, Durham, NC; Cambridge University Hospitals NHS Foundation Trust, Department of Oncology, Cambridge, United Kingdom; The University of Chicago, Chicago, IL; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Kamanos Cancer Institute, Wayne State University, Detroit, MI; Cleveland Clinic, Cleveland, OH; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; BC Cancer Agency, Vancouver, BC, Canada; Pharmanet i3, The Woodlands, TX; Duke Clinical Research Institute, Durham, NC

**TPS4593: A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC)**

General Poster Session: Genitourinary (Nonprostate) Cancer  
Mon, Jun 3 8:00 AM - 11:45 AM; S Hall A2  
J Clin Oncol 31, 2013 (suppl; abstr TPS4593)

Author(s): Asim Amin, Marc S. Ernstoff, Jeffrey R. Infante, Daniel Yick Chin Heng, Brian I. Rini, Elizabeth R. Plimack, David F. McDermott, Christian K. Kollmannsberger, Martin Neil Reaume, Jennifer L. Spratlin, Jennifer J. Knox, Martin Henner Voss, Sumanta Kumar Pal, Yun Shen, Arindam Dhar, Hans J. Hammers; Levine Cancer Institute, Charlotte, NC; Dartmouth Hitchcock Medical Center, Geisel School of Medicine/ Norris Cotton Cancer Center, Lebanon, NH; Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA; BC Cancer Agency, Vancouver, BC, Canada; The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Princess Margaret Cancer Center, Toronto, ON, Canada; Memorial Sloan-Kettering Cancer Center, New York, NY; City of Hope Comprehensive Cancer Center, Duarte, CA; Bristol-Myers Squibb, Princeton, NJ; Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

**TPS4595: Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma**

General Poster Session: Genitourinary (Nonprostate) Cancer
6538: Trial prospector: An automated clinical trials eligibility matching program
General Poster Session: Health Services Research
Mon, Jun 3 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 6538)
Author(s): Andrew J. Parchman, Guo-Qiang Zhang, Patrick Mergler, Jill Bamholtz-Sloan, Robert Lanese, Dawn M. Miller, Chris Opper, Satya Sahoo, Shiqiang Tao, Joseph Teagno, James Warfe, Neal J. Meropol; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

6577: The importance of early treatment to decrease therapy-related complications in Burkitt lymphoma (BL), Burkitt-like leukemia/lymphoma (BLL), and acute lymphocytic leukemia (ALL) treated with disease-specific systemic therapy
General Poster Session: Health Services Research
Mon, Jun 3 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 6577)
Author(s): Alaa Muslimani, Adewale Fawole, Hamed Daw, Timothy Peter Spiro, Hong Ye, Ishmael A. Jaiyesimi; Billings Clinic Cancer Center, Billings, MT; Fairview Hospital, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Cancer Center, Cleveland, OH; William Beaumont Hospital, Royal Oak, MI; William Beaumont Hospital, William Beaumont School of Medicine, Oakland University, Royal Oak, MI

9545: Measures of polypharmacy and chemotherapy toxicity in older adults with cancer
General Poster Session: Patient and Survivor Care
Mon, Jun 3 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 9545)
Author(s): Ronald John Maggiore, Tao Feng, William Dale, Cary Philip Gross, William P. Tew, Supriya Gupta Mohile, Cynthia Owusu, Heidi D. Klepin, Stuart M. Lichtman, Ajeet Gajra, June M McKoy, Vani Katheria, Rupal Ramani, Reena J ayani, Jaycen Brown, Arti Humia; University of Chicago Medical Center, Chicago, IL; City of Hope, Duarte, CA; The University of Chicago Medical Center, Chicago, IL; Yale School of Medicine, New Haven, CT; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester Medical Center, Rochester, NY; Case Western Reserve University, Cleveland, OH; Wake Forest University, School of Medicine, Winston-Salem, NC; Upstate Medical
University, Syracuse, NY; Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

9638: Symptom clusters and demographic characteristics in advanced cancer
General Poster Session: Patient and Survivor Care
Mon, Jun 3 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 9638)
Author(s): Aynur Aktas, Declan Walsh, Lisa A. Rybicki, Anne Fitz; Harry R. Horvitz Center for Palliative Medicine and Supportive Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland, OH; Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

11091: Tumoral MET/HGF expression and MET gene amplification in patients with ALK 2p23 fusion driven lung cancer
General Poster Session: Tumor Biology
Mon, Jun 3 1:15 PM - 5:00 PM; S Hall A2
J Clin Oncol 31, 2013 (suppl; abstr 11091)
Author(s): Yan Feng, Eugen C. Minca, Wei Zhang, Lihong Yin, Nathan A. Pennell, Carol Farver, Angen Liu, Raymond R. Tubbs, Patrick C. Ma; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, OH

ONLINE ONLY ABSTRACTS

e13030: Association of the development of bone metastases with the development of brain metastases in patients with non-small cell lung cancer
Central Nervous System Tumors
J Clin Oncol 31, 2013 (suppl; abstr e13030)
Author(s): Mohamed Salem, Paul Eison, Nathan A. Pennell, Ammar Sukari, Sherif El-Refai, Khaled B. Ali, Shirish M. Gadgeel, Nicholas Szerlip, Antoinette J. Wozniak; Kamanos Cancer Institute, Wayne State University, Detroit, MI; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH; University of Florida, Gainesville, FL; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Wayne State University, Detroit, MI

e13031: Risk factors for venous thromboembolism in elderly patients with glioblastoma
Central Nervous System Tumors
J Clin Oncol 31, 2013 (suppl; abstr e13031)
Author(s): Neda Hashemi-Sadraei, Roozbeh Sharif, Jorge Machiado, Saurabh Dahiya, Manmeet Singh Ahluwalia; University of Texas Health Science Center at Houston, Houston, TX; The University of Texas Medical Branch, Galveston, TX; Cleveland Clinic, Cleveland, OH
e13521: Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
J Clin Oncol 31, 2013 (suppl; abstr e13521)
Author(s): Kriti Mittal, Henry B. Koon, Paul Elson, Pierre L. Triozzi, Afshin Dowlati, Ernest C. Borden, Brian I. Rini; Cleveland Clinic, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

e14634: Preclinical model for combined effects of metformin and vitamin D3 on colitis-associated colon neoplasia
Gastrointestinal (Colorectal) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e14634)
Author(s): Wan Li, Qi-Long Wang, Hong-Xia Li, Chun-Yang Li, Nathan A. Berger, Li Li, Yongjie Wu; Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Department of Pharmacology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China; Case Western Reserve University, Cleveland, OH

e14711: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis
Gastrointestinal (Colorectal) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e14711)
Author(s): Halla Sayed Nimeiri, Yang Feng, Paul J. Catalano, Neal J. Meropol, Bruce J. Giannoni, Elin R. Sigurdson, James A. Martenson, Robert P. Whitehead, Frank A. Sinicrope, Robert J. Mayer, Peter J. O'Dwyer, Al Bowen Benson, Eastern Cooperative Oncology Group; Northwestern University, Feinberg School of Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Mayo Clinic, Rochester, MN; Medical University of South Carolina, Charleston, SC; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

e15000: A retrospective analysis of the role of gefitinib in the definitive management of esophageal/gastroesophageal junction (E/GEJ) cancer
Gastrointestinal (Noncolorectal) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15000)
Author(s): Davendra Sohal, Thomas W. Rice, Lisa A. Rybicki, Cristina P. Rodriguez, Gregory M. M. Videtic, Jerold P. Saxton, Sudish C. Murthy, David P. Mason, Brooke Elizabeth Phillips, Raymond R. Tubbs, Thomas Plesec, Michael J. McNamara, Denise I. Ives, Joanna Bodmann, David J. Adelstein; Cleveland Clinic, Cleveland, OH; Cleveland
e15015: Local failure after liver resection for hepatocellular carcinoma
Gastrointestinal (Noncolorectal) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15015)
Author(s): Elisha T. Fredman, Aryavarta M. S. Kumar, Galal El-Gazzaz, Federico Aucejo, Christopher Coppa, May Abdel-Wahab; Case Western Reserve University School of Medicine, Cleveland, OH; Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH; Department of Hepato-pancreato-biliary & Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH; Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH; Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH

e15097: Translational significance of a newly identified hepatocellular carcinoma tumor suppressor gene on chromosome 8p
Gastrointestinal (Noncolorectal) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15097)
Author(s): Han Chong Toh, Francis Enane, Marissa Teo, Hideki Makishima, JoAnna Ng, Chit Lai Chee, Soo Fan Ang, Kiat Hon Lim, Yogen Saunthararajah; National Cancer Center, Singapore, Singapore; Cleveland Clinic, Cleveland, OH; National Cancer Center Singapore, Singapore, Singapore; Cleveland Clinic, Cleveland, OH; Department of Pathology, Singapore General Hospital, Singapore

e15518: First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC)
Genitourinary (Nonprostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15518)
Author(s): Lauren Christine Harshman, Nils Kroeger, Sun Young Rha, Frede Donskov, Lori Wood, Srinivas Kiran Tantravahi, Ulka N. Vaishampayan, Brian I. Rini, Jennifer J. Knox, Scott A. North, Mary J. MacKenzie, Takeshi Yuasa, Sandy Srinivas, Sumanta Kumar Pal, Daniel Yick Chin Heng, Toni K. Choueiri; Dana-Farber Cancer Institute, Boston, MA; Tom Baker Cancer Centre, Calgary, AB, Canada; Yonsei Cancer Center/Yonsei University College of Medicine, Seoul, South Korea; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; London Regional Cancer Program, London, ON, Canada; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Stanford Medical Center, Stanford, CA; City of Hope, Duarte, CA

e15534: Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma
Genitourinary (Nonprostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15534)
Author(s): Yana George Najjar, Paul Elson, Jorge A. Garcia, Robert Dreicer, Brian I. Rini; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**e15537: Graded prognostic assessment index for renal cell carcinoma with brain metastases**
Genitourinary (Nonprostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15537)
Author(s): Rohan Garje, Saurabh Dahiya, Vyshak Alva Venur, Lingling Du, Kwabena Osei-Boateng, Paul Elson, John H. Suh, Samuel T. Chao, Manmeet Singh Ahluwalia; Cleveland Clinic/Fairview, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland Clinic, OH; Cleveland Clinic Foundation, Cleveland Clinic, OH; Cleveland Clinic Taussig Cancer Foundation, Cleveland, OH; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH

**e15624: Retrospective analysis of risk factors for fatigue in clinical trial patients (pts) with metastatic renal cell carcinoma (mRCC)**
Genitourinary (Nonprostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e15624)
Author(s): Martin Eric Gore, Viktor Gruenwald, Robert John Motzer, David I. Quinn, Brian I. Rini, Xun Lin, Julia Jane Perkins, Ronit Simantov, Toni K. Choueiri; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Pfizer Oncology, San Diego, CA; Pfizer Oncology, New York, NY; Dana-Farber Cancer Institute, Boston, MA

**e16004: Development of a nomogram to predict for all-cause and cancer-specific mortality in high-risk prostate cancer treated by external beam radiotherapy and androgen deprivation**
Genitourinary (Prostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e16004)
Author(s): Rahul D. Tendulkar, Michael W. Kattan, Changhong Yu, Chandana A. Reddy, Kevin L. Stephens, Patrick Kupelian, Andrew J. Stephenson; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH; University of California, Los Angeles, Los Angeles, CA; Center for Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland, OH

**e16022: Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib)**
Genitourinary (Prostate) Cancer
J Clin Oncol 31, 2013 (suppl; abstr e16022)
Author(s): Jorge A. Garcia, Paul Elson, Matthew M. Cooney, Allison Janine Tyler, Victoria Rezash, Ernest C. Borden, Robert Dreicer; Cleveland Clinic, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH
**e16518: Lymph node metastases in endocervical adenocarcinoma: Correlation with Silva pattern of invasion**
Gynecologic Cancer
J Clin Oncol 31, 2013 (suppl; abstr e16518)
Author(s): Joanne KL Rutgers, Richard J Zaino, Robert H Young, Brigitte M. Ronnett, Teri A. Longacre, Isabel Alvarado-Cabrero, Kay J. Park, Andres Roma, Kathryn Osann, Elvio Silva, MD Anderson Collaborative Study: Endocervical Adenocarcinoma; University of California, Irvine, Long Beach, CA; Hershey Medical Center, Hershey, PA; Harvard Medical School, Boston, MA; Johns Hopkins School of Medicine, Baltimore, MD; Stanford University Medical Center, Stanford, CA; Mexican Oncology Hospital, Mexico City, Mexico; Memorial Sloan-Kettering Cancer Center, New York, NY; Cleveland Clinic, Cleveland, OH; University of California, Irvine, Orange, CA; Cedars-Sinai Medical Center, Los Angeles, California The University of Texas MD Anderson Cancer Center, Houston, TX

**e17530: Clinical impact of an online tool to guide choice of therapy (Tx) for patients (Pts) with advanced renal cell carcinoma (RCC)**
Health Services Research
J Clin Oncol 31, 2013 (suppl; abstr e17530)
Author(s): Timothy A Quill, Brian I. Rini, Eric Jonasch, Andrew Bowser, J im A. Mortimer, Robert J ohn Motzer; Clinical Care Options, LLC, Reston, VA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY

**e18526: Use of CD30 expression in human malignant mesothelioma as a novel therapeutic target**
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
J Clin Oncol 31, 2013 (suppl; abstr e18526)
Author(s): Afshin Dowlati, Snehal Dabir, Adam Kresak, Michael Yang, Gary Wildey; University Hospitals Seidman Cancer Center; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH

**e19012: The association of toxicities and outcomes with circulating endothelial cells (CEC) in non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (Bev)**
Lung Cancer - Non-small Cell Metastatic
J Clin Oncol 31, 2013 (suppl; abstr e19012)
Author(s): Nooshin Hashemi Sadraei, Lingling Du, Ruchi Yadav, Ronald Grane, Barbara Jacobs, John Hamulak, Patrick C. Ma, Nathan A. Pennell, Paul Elson, Ernest C. Borden; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland Clinic, OH; Cleveland Clinic, Cleveland, OH; Clevland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic Foundation-Department of Translational Hematology and Oncology Research, Cleveland, OH
**e19025: Predictors of outcome for pemetrexed (Pem) in metastatic NSCLC (mNSCLC)**

Lung Cancer - Non-small Cell Metastatic

J Clin Oncol 31, 2013 (suppl; abstr e19025)

Author(s): Cortney Vanderbilt Jones, Lingling Du, Paul Elson, Tarek Mekhail, Nathan A. Pennell, Nooshin Hashemi Sadraei; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland Clinic, OH; Cleveland Clinic Quantitative Health Sciences, Cleveland, OH; Florida Hospital, Orlando, FL; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

**e20572: Weight loss in solid tumors: Clinical features and prognostic importance**

Patient and Survivor Care

J Clin Oncol 31, 2013 (suppl; abstr e20572)

Author(s): Shiva Shrotriya, Aynur Aktas, Bassam N. Estfan, Lisa A. Rybicki, Declan Walsh; Harry R. Horvitz Center for Palliative Medicine and Supportive Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH

**e20597: Are validated symptom assessment instruments comprehensive? “Orphan” and “champion” symptoms**

Patient and Survivor Care

J Clin Oncol 31, 2013 (suppl; abstr e20597)

Author(s): Shirley Thomas, Declan Walsh, Aynur Aktas; Harry R. Horvitz Center for Palliative Medicine and Supportive Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**e20633: Health care worker attitudes about clinical trials at a comprehensive cancer center**

Patient and Survivor Care

J Clin Oncol 31, 2013 (suppl; abstr e20633)

Author(s): Erica Leigh Campagnaro, Seunghee Margevicius, Barbara J. Daly, Jennifer Rachel Eads, Tyler G. Kinzy, Tasnuva Munir Liu, Sharon Manne, Dawn M. Miller, Mark D. Schluchter, Neal J. Meropol; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cancer Institute of New Jersey, New Brunswick, NJ

**e22032: CARD8/BCL-2 cascade in early adaptive drug resistant tumor escape against targeted inhibitors in NSCLC**

Tumor Biology

J Clin Oncol 31, 2013 (suppl; abstr e22032)

Author(s): Rakesh K. Bagai, Wei Zhang, Patrick Leahy, Lihong Yin, Patrick C. Ma; Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH
e22042: ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study
Tumor Biology
J Clin Oncol 31, 2013 (suppl; abstr e22042)
Author(s): Fred R. Hirsch, Yasushi Yatabe, Manfred Dietel, Lynette M. Sholl, Ming Sound Tsao, Ed Schuuring, Raymond R. Tubbs; University of Colorado Cancer Center, Aurora, CO; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan; Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany; Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA; Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada; University Medical Center Groningen, Groningen, Netherlands; Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, OH

e22077: Effect of exogenous triiodothyronine [T3] on free thyroxine depletion and tumor response: A compassionate care study
Tumor Biology
J Clin Oncol 31, 2013 (suppl; abstr e22077)
Author(s): Aleck Hercbergs; Cleveland Clinic, Cleveland, OH

e22158: Dynamic real-time imaging of marrow-resident neutrophils interacting with human mesenchymal stem cells during systemic lipopolysaccharide challenge
Tumor Biology
J Clin Oncol 31, 2013 (suppl; abstr e22158)
Author(s): Alex Yee-Chen Huang, Jay T. Myers, Deborah Sim Barkauskas; Case Western Reserve University, Cleveland, OH